ArticleAmerican journal of clinical and experimental immunology2025
Identification of immune infiltration-related ZNF480 for predicting prognosis in breast cancer.
Article in American journal of clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DPT has potential to be a prognostic biomarker and its correlation with immune infiltrates in prostate cancer.American journal of clinical and experimental immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is one of the most common cancers in women with high morbidity and mortality. ZNF480, a member of the KRAB-ZNFs family, correlates with cancer progression. However, its role in the development and progression of breast cancer remains unclear.
methodsWe utilized transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases of breast cancer patients to investigate the potential pro-cancer role of ZNF480, including differential expression of ZNF480 in breast cancer, prognostic value, clinicopathological features, immune cell infiltration relevance and function enrichment analysis.
resultsOur results indicate that ZNF480 is upregulated in breast cancer and is correlations with survival, clinical stage, race and tumor subtype in breast cancer patients. Additionally, immune infiltration analysis revealed significant negative correlations between ZNF480 expression and multiple tumor infiltrating immune cells, including aDC, B cells, CD8 T cells, Cytotoxic cells, DC, iDC, Macrophages, Neutrophils, NK CD56bright cells, NK CD56dim cells, NK cells, pDC, T cells, Tem, TFH and Th1 cells, whereas a significant positive correlation was observed with the infiltration of T helper cells, Tcm, Tgd and Th2 cells. Furthermore, functional enrichment analysis indicated that ZNF480 may be involved in Angiogenesis, Allograft rejection, TNFα signaling via NFκB, Coagulation, IL6 Jak STAT3 signaling, Inflammatory response, Interferon gamma response and other processes.
conclusionZNF480 is highly expressed in breast cancer and correlates with immune cell infiltration, and may be a candidate prognostic biomarker, which may assist in breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.